Janus Henderson Group
EIGR

Janus Henderson Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Janus Henderson Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,853
Closed -$1.55M – 2519
2022
Q3 		$1.55M Buy
+6,853
New +$1.68M ﹤0.01% 1132

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Janus Henderson Group's EIGR Position: Q4 2022 in Review

Janus Henderson Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 6,853 shares — an estimated $1.55M sold.

Janus Henderson Group first reported a position in EIGR in Q3 2022 and held it in 1 quarter. The position peaked at $1.55M in Q3 2022. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

  • Janus Henderson Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Janus Henderson Group sold 6,853 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $1.55M.
  • Janus Henderson Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2022 and held it in 1 quarter.
  • Janus Henderson Group's Eiger BioPharmaceuticals, Inc. position peaked at $1.55M in Q3 2022.
  • 81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Janus Henderson Group's 13F filing for Q4 2022, filed 14 Feb 2023.